Baird analyst Brian Skorney raised the firm’s price target on Soleno Therapeutics (SLNO) to $121 from $105 and keeps an Outperform rating on the shares. The firm updated its model after Q2 Vykat sales blew out expectations.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLNO:
- Soleno Therapeutics Announces Public Stock Offering
- Soleno Therapeutics prices 2.35M sharesat $85.00 in public offering
- Soleno Therapeutics announces proposed $200M public offering
- Soleno Therapeutics sees Q2 VYKAT XR revenue $31M-$33M
- Soleno Therapeutics price target raised to $115 from $108 at Stifel